(Q42836349)

8 November 2017

title

Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis (English)

1 reference

8 November 2017

Chee-Yean Loo

1

1 reference

8 November 2017

Mohd Shahrir Mohamed Said

2

1 reference

8 November 2017

Rozita Mohd

3

1 reference

8 November 2017

Abdul Halim Abdul Gafor

4

1 reference

8 November 2017

Rashidi Saidin

5

1 reference

8 November 2017

Norma Abdul Halim

6

1 reference

8 November 2017

Mei Kwi Chua

7

1 reference

8 November 2017

Norella C T Kong

8

1 reference

8 November 2017

publication date

3 November 2010

1 reference

Transfusion and Apheresis Science

8 November 2017

published in

1 reference

8 November 2017

volume

43

1 reference

8 November 2017

issue

3

1 reference

8 November 2017

page(s)

335-340

1 reference

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Incidence of infection in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Therapeutic plasma exchange: complications and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2010.10.003

10.1016/J.TRANSCI.2010.10.003

7 January 2021

Identifiers

DOI

1 reference

8 November 2017

1 reference